Wikipedia

User:Mr. Ibrahem/Insulin degludec

< User:Mr. Ibrahem
Mr. Ibrahem/Insulin degludec
An insulin degludec hexamer. A chains are chartreuse, B chains are tan, and the central zinc atom is teal. From PDB: 4AKJ​.
Clinical data
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Subcutaneous
Drug classInsulin (long-acting)[1]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only[2]
  • In general: ℞ (Prescription only)
Identifiers
  • B29N(ε)-ω-carboxypentadecanoyl-γ-L-glutamyl desB30 human insulin
Chemical and physical data
FormulaC274H411N65O81S6
Molar mass6104.04 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Insulin degludec, under the brand name Tresiba is an long-acting insulin used to treat type I and type II diabetes.[1] It once daily by injection under the skin.[1] Onset of effects occur within 90 minutes and last for more than 42 hours.[1] After a few days it has a steady effects at all hours.[3]

Common side effects include low blood sugar, allergic reactions, pain at the site of injection, itchiness, rash, weight gain, and lipodystrophy.[1] It has a lower risk of low blood sugar compared to long acting detemir and glargine.[4] Other side effects may include low potassium.[1] In pregnancy NPH insulin is preferred.[5] It is a form of insulin made by recombinant DNA technology and than further modified.[5][1]

Insulin degludec was approved for medical use in Europe in 2013 and the United States in 2015.[6][1] In the United Kingdom a 300 unit pen costs the NHS about £9 as of 2021.[5] In the United States this amount costs about 100 USD.[7] In 2019, it was the 168th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[8][9] It is also available in combination with liraglutide.[1]

References

edit
  1. ^ a b c d e f g h i j k "Insulin Degludec Monograph for Professionals". Drugs.com. Archived from the original on 21 October 2020. Retrieved 26 November 2021.
  2. ^ "Tresiba EPAR". European Medicines Agency (EMA). Archived from the original on 22 January 2021. Retrieved 15 January 2021.
  3. ^ "Tresiba Summary of product characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 2016-03-04. Retrieved 2021-01-16.
  4. ^ Ton, Joey (21 March 2022). "#311 "Ultralong"-acting insulin for diabetes: How long is long enough?". CFPCLearn. Archived from the original on 1 February 2023. Retrieved 14 June 2023.
  5. ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 757. ISBN 978-0857114105.
  6. ^ "Tresiba". Archived from the original on 22 January 2021. Retrieved 26 November 2021.
  7. ^ "Tresiba Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 8 October 2021. Retrieved 26 November 2021.
  8. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  9. ^ "Insulin Degludec - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Insulin_degludec&oldid=1170461496"